TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A systematic review and meta-analysis covering nearly 16 million people found ADHD was associated with higher all-cause mortality, including higher reported risks of suicide, injury and natural-cause death. ADHD medication use was associated with lower all-cause mortality, but that result came from only three studies and may reflect differences between treated and untreated people.
A systematic review and meta-analysis of 19 studies involving 15,920,970 people found that attention-deficit hyperactivity disorder (ADHD) was associated with a 71% higher relative risk of all-cause mortality than no ADHD, complementing research on ADHD and dementia risk. The researchers also reported higher relative risks of suicide, injury and natural-cause mortality, while a lower mortality risk associated with ADHD medication was based on only three studies and should be interpreted cautiously.
In the analysis, ADHD was associated with a hazard ratio of 1.71 for all-cause mortality (95% confidence interval, 1.31 to 2.24). The reported hazard ratios were 1.89 for suicide, 1.55 for intentional or unintentional injury, and 1.27 for natural-cause mortality. These figures describe relative associations across the included studies; the report does not establish that ADHD itself caused the deaths or provide an individual person’s absolute risk.
Lead author Joshua Stott, PhD, of University College London, and colleagues reported their findings in JAMA Network Open. Their review included peer-reviewed quantitative research published through July 2025, covering people of all ages. ADHD was identified using varied methods, including diagnostic criteria, self-identification, measures of ADHD traits and genetic risk scores. Twelve of the 19 studies contributed results to the meta-analyses.
The medication analysis found ADHD medication use associated with a 25% lower relative risk of all-cause mortality (hazard ratio 0.75; 95% confidence interval, 0.64 to 0.87). That estimate was drawn from just three studies. The authors cautioned that differences in health-care access, socioeconomic circumstances, ADHD severity, treatment adherence and co-existing psychiatric conditions could affect comparisons between people who did and did not receive medication.
Diagnosis and Care in Focus
The findings point to mortality as one of several serious outcomes that researchers and clinicians may need to study alongside ADHD symptoms and daily functioning. The pattern across suicide, injury and natural causes suggests that the association may involve multiple pathways rather than a single cause. The study itself does not determine which factors explain the higher risks.
Stott told MedPage Today that the results do not mean that everyone with ADHD will die young or that higher mortality is inevitable. He said the findings support access to accurate diagnosis and treatment. That message is relevant to adults in particular: the article notes that ADHD can go unrecognized into adulthood, and that some people diagnosed as adults do not receive treatment. The study did not test whether broader diagnosis or treatment would reduce population mortality.
The medication result may draw attention because it points in a potentially different direction from the overall association. But with only three studies in that analysis and possible confounding, it is not evidence that medication prevents death. Treatment decisions require individual clinical assessment, not an interpretation of this pooled result as a guaranteed benefit.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
As an affiliate, we earn on qualifying purchases.
How Researchers Built the Review
Earlier studies had reported elevated mortality among people with ADHD, and some had suggested a difference in life expectancy. The new review brought together studies across age groups and settings to estimate associations with all-cause and cause-specific mortality. It analyzed nine studies for all-cause mortality, five for suicide, four for injury, three for natural-cause mortality and three for mortality among people using ADHD medication.
The evidence was not uniform in magnitude. The researchers reported substantial statistical heterogeneity in the first four analyses, meaning results varied across studies, although the studies consistently showed higher mortality in ADHD groups. The medication analysis had moderate heterogeneity. Differences in study populations, diagnostic approaches and access to care across countries may have contributed to variation.
The article cites U.S. Centers for Disease Control and Prevention estimates that 15 million adults in the United States have ADHD and nearly one in three take stimulant medication. It also reports that about 7 million children ages 3 to 17 have an ADHD diagnosis, based on a national parent survey. These figures describe U.S. prevalence and treatment, not the populations or outcomes of the review alone.
“These findings do not suggest that everyone with ADHD will die young, nor do they suggest that increased mortality is impossible to change or inherent to ADHD.”
— Joshua Stott, PhD, lead author, speaking to MedPage Today
Limits of the Mortality Evidence
The review reports associations, not proof that ADHD causes higher mortality or that medication lowers it. The medication finding is especially uncertain because it relies on only three studies and may be affected by confounding: people receiving treatment may differ from untreated people in health, access to care, illness severity and other factors.
The study also combined evidence gathered using different definitions of ADHD and from varied populations. The authors noted gender imbalances in many studies, while the review population was 63.9% male. Statistical heterogeneity in several analyses means the size of the association varied across studies. The available source does not establish which mechanisms account for the results, whether they apply equally across age groups, or what the absolute mortality risk is for a particular person.
Further Evidence on Treatment
The review covers research available through July 2025; it does not report a planned follow-up or a new clinical trial. A key next step for research would be to test the findings in larger, well-characterized populations and distinguish the effects of ADHD, co-existing conditions and access to treatment. More evidence would also be needed to assess whether medication is associated with lower mortality after accounting for differences between treated and untreated groups.
For now, the reported results add to evidence of a mortality association but do not establish an individual prognosis or a mortality-prevention effect from medication. The authors’ stated emphasis is on access to accurate diagnosis and care, while the reasons for the observed differences and the strength of the medication association remain open questions.
Key Questions
What did the review find about ADHD and mortality?
Across the included studies, ADHD was associated with a 71% higher relative risk of all-cause mortality. The analysis also reported higher relative risks of suicide, injury and natural-cause mortality. These are group-level associations, not proof of causation or an individual’s absolute risk.
Does this mean a person with ADHD will die younger?
No. Lead author Joshua Stott told MedPage Today that the findings do not mean everyone with ADHD will die young. The review describes average associations across studies and cannot predict an individual person’s outcome.
Did ADHD medication reduce mortality?
Medication use was associated with a lower relative risk of all-cause mortality, but the analysis included only three studies. The researchers cautioned that differences between treated and untreated people could explain some or all of the association; the result does not prove medication prevents death.
What causes the higher mortality association?
The review did not establish a cause. Its authors discussed possible pathways, including injury risks, co-existing mental health conditions, smoking and alcohol use, barriers to health care, and cardiovascular or metabolic disorders. These are potential explanations, not findings that the review proved.
How large was the evidence base?
The review included 19 studies and 15,920,970 participants, with 12 studies contributing to meta-analyses. The number of studies differed by outcome; for example, nine contributed to the all-cause mortality analysis and three to the medication analysis.
Source: rss
